5-fluorowillardiine has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 1 studies
| Studies (5-fluorowillardiine) | Trials (5-fluorowillardiine) | Recent Studies (post-2010) (5-fluorowillardiine) | Studies (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) | Trials (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) | Recent Studies (post-2010) (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) |
|---|---|---|---|---|---|
| 29 | 0 | 8 | 3,859 | 8 | 1,052 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brotchie, JM; Crossman, AR; Silverdale, MA | 1 |
1 other study(ies) available for 5-fluorowillardiine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alanine; Animals; Apomorphine; Autoradiography; Binding, Competitive; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agonists; Female; Ligands; Macaca mulatta; Male; Organ Specificity; Parkinson Disease, Secondary; Pyrimidines; Radioligand Assay; Receptors, AMPA | 2002 |